The NIA Interventions Testing Program Shows that Fisetin Does Not Extend Life in Mice

The latest results from the NIA Interventions Testing Program (ITP) were recently published. The ITP conducts the most rigorous of animal life span studies, frequently demonstrating that earlier promising results were incorrect. The most interesting outcome from this batch of different interventions is that fisetin, demonstrated to clear senescent cells in mice and improve health measures, did not extend life. In contrast, dasatinib and quercetin, the most well-studied senolytic, has been shown by other groups to extend life in mice, by 36% in one study. This is puzzling! We might theorize that either fisetin at the senolytic doses used in the ITP study (more frequent dosing for a longer period of time than I might have chosen) produces meaningful harmful side-effects in comparison to less frequent dasatinib and quercetin dosing, or that an ITP-run life span study for dasatinib and quercetin treatment would show no benefit to life span. The former sounds more plausible than the latter, but the data is the data. The ITP researchers consider that the issue may be differences between mouse strains used in various fisetin studies, and this is also interesting if the case, that senescent cell burden and type might be different enough in different strains to produce quite different outcomes. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not signif...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs